 NeuroSense Therapeutics Ltd NASDAQ: NRSN has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimers disease AD. Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating. 